BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 63,588 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. trimmed its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 30.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 142,426 shares of the medical research company's stock after selling 63,588 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned approximately 0.28% of Charles River Laboratories International worth $28,054,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of CRL. O Shaughnessy Asset Management LLC acquired a new position in shares of Charles River Laboratories International during the 1st quarter worth approximately $415,000. Natixis acquired a new position in shares of Charles River Laboratories International during the 1st quarter worth approximately $1,058,000. CreativeOne Wealth LLC acquired a new position in shares of Charles River Laboratories International during the 1st quarter worth approximately $201,000. Axxcess Wealth Management LLC boosted its position in shares of Charles River Laboratories International by 54.8% during the 1st quarter. Axxcess Wealth Management LLC now owns 2,094 shares of the medical research company's stock worth $567,000 after acquiring an additional 741 shares in the last quarter. Finally, Advisors Asset Management Inc. boosted its position in shares of Charles River Laboratories International by 50.4% during the 1st quarter. Advisors Asset Management Inc. now owns 3,359 shares of the medical research company's stock worth $910,000 after acquiring an additional 1,126 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Trading Up 0.8 %

NYSE CRL traded up $1.58 during mid-day trading on Friday, reaching $195.77. 575,717 shares of the stock were exchanged, compared to its average volume of 863,318. Charles River Laboratories International, Inc. has a one year low of $176.48 and a one year high of $275.00. The stock has a 50 day simple moving average of $194.99 and a 200-day simple moving average of $206.07. The stock has a market cap of $10.01 billion, a P/E ratio of 24.50, a P/E/G ratio of 5.01 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping analysts' consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. During the same quarter last year, the firm earned $2.72 earnings per share. Charles River Laboratories International's quarterly revenue was down 1.6% on a year-over-year basis. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 10.19 EPS for the current year.

Charles River Laboratories International declared that its Board of Directors has initiated a share repurchase plan on Wednesday, August 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to repurchase up to 9.6% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's board of directors believes its shares are undervalued.

Insider Buying and Selling

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the firm's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts recently issued reports on CRL shares. JPMorgan Chase & Co. lowered shares of Charles River Laboratories International from an "overweight" rating to a "neutral" rating and reduced their price target for the stock from $270.00 to $205.00 in a research report on Thursday, August 8th. Barclays dropped their price objective on shares of Charles River Laboratories International from $230.00 to $210.00 and set an "equal weight" rating for the company in a research note on Thursday, August 8th. UBS Group increased their price objective on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Evercore ISI increased their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an "in-line" rating in a research note on Thursday, November 7th. Finally, Citigroup downgraded shares of Charles River Laboratories International from a "neutral" rating to a "sell" rating and dropped their price objective for the company from $215.00 to $175.00 in a research note on Tuesday, October 1st. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $214.38.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).